Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$11.4B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge its financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases. Operating in the health care sector, BioMarin's work is crucial as it addresses unmet medical needs and aims to improve the quality of life for patients with rare conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly missing estimates. The stock reacted positively, increasing by 2.59% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given BioMarin's history of beating EPS estimates. However, the lack of recent guidance adds uncertainty.

Bull Case

If BioMarin can demonstrate strong revenue growth and positive updates on its product pipeline, it could lead to a significant stock rally.

Bear Case

Conversely, if the company reports disappointing earnings or offers weak guidance, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated guidance on revenue growth for the upcoming quarters?

This will help investors assess the company's ability to maintain momentum and meet market expectations.

Are there any significant updates on the product pipeline that could impact future earnings?

Insights into the product pipeline could influence investor sentiment and expectations for future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin's product pipeline to drive future growth, particularly in light of recent advancements.

Supporting Evidence

The company has a strong track record of beating EPS estimates, which could continue this quarter.

Options are pricing in a 15.32% move, suggesting that traders are anticipating significant volatility, which may not align with the company's historical performance.

Key Risk

If the product pipeline shows significant advancements, it could lead to a positive surprise that challenges current market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will set the tone for future growth and investor confidence.

Bull Confirmed If

A revenue growth rate of over 15% year-over-year would confirm the bullish outlook.

Bear Confirmed If

If revenue growth falls below 5%, it would signal significant challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could rise by around 2.36%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.37%, reflecting disappointment and potential concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the revenue growth forecast for the next quarter.
2Details on the status of the product pipeline and any upcoming launches.
3Management's commentary on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Any changes in strategic direction or focus areas for the company.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for serious genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and will help gauge its financial health this quarter.

N/A

Revenue Growth

Revenue growth is essential for understanding the company's market performance and demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly missing estimates. The stock reacted positively, increasing by 2.59% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given BioMarin's history of beating EPS estimates. However, the lack of recent guidance adds uncertainty.

Bull Case

If BioMarin can demonstrate strong revenue growth and positive updates on its product pipeline, it could lead to a significant stock rally.

Bear Case

Conversely, if the company reports disappointing earnings or offers weak guidance, it could lead to a sharp decline in the stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated guidance on revenue growth for the upcoming quarters?

This will help investors assess the company's ability to maintain momentum and meet market expectations.

Are there any significant updates on the product pipeline that could impact future earnings?

Insights into the product pipeline could influence investor sentiment and expectations for future revenue.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin's product pipeline to drive future growth, particularly in light of recent advancements.

Supporting Evidence

The company has a strong track record of beating EPS estimates, which could continue this quarter.

Options are pricing in a 15.32% move, suggesting that traders are anticipating significant volatility, which may not align with the company's historical performance.

Key Risk

If the product pipeline shows significant advancements, it could lead to a positive surprise that challenges current market expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will set the tone for future growth and investor confidence.

Bull Confirmed If

A revenue growth rate of over 15% year-over-year would confirm the bullish outlook.

Bear Confirmed If

If revenue growth falls below 5%, it would signal significant challenges ahead.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests the stock could rise by around 2.36%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.37%, reflecting disappointment and potential concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the revenue growth forecast for the next quarter.
2Details on the status of the product pipeline and any upcoming launches.
3Management's commentary on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Any changes in strategic direction or focus areas for the company.